 TOKYO , July 25, 2022 PRNewswire -- Eisai Co. Ltd Headquarters: Toyoko, CEO: Haruo Naito, Eisai announced today that the company will present research from its Alzheimers disease AD pipeline, including new data for lecanemab BAN2401, an investigational anti-amyloid beta Aβ protofibril antibody for the treatment of mild cognitive impairment MCI due to Alzheimers disease AD and mild AD collectively known as early AD with confirmed presence of amyloid pathology in the brain, at the Alzheimers Association International Conference AAIC to be held in San Diego, CA and virtually from July 31 to August 4, 2022. Eisai will present data and research in three oral and 18 poster presentations at the meeting. 